Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in uniQure N.V., ADMA Biologics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how uniQure N.V., ADMA Biologics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About uniQure N.V., ADMA Biologics and Inc.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Latest Biotechnology and uniQure N.V., ADMA Biologics, Inc. Stock News

As of July 30, 2026, uniQure N.V. had a $2.9 billion market capitalization, compared to the Biotechnology median of $251.9 million. uniQure N.V.’s stock is up 81.1% in 2026, up 11.2% in the previous five trading days and up 208.85% in the past year.

Currently, uniQure N.V. does not have a price-earnings ratio. uniQure N.V.’s trailing 12-month revenue is $18.7 million with a % net profit margin. Year-over-year quarterly sales growth most recently was 9.4%. Analysts expect adjusted earnings to reach $-3.880 per share for the current fiscal year. uniQure N.V. does not currently pay a dividend.

As of July 30, 2026, ADMA Biologics, Inc. had a $2.0 billion market cap, putting it in the 54th percentile of all stocks. ADMA Biologics, Inc.’s stock is down 53.8% in 2026, up 2% in the previous five trading days and down 52.52% in the past year.

Currently, ADMA Biologics, Inc.’s price-earnings ratio is 12.7. ADMA Biologics, Inc.’s trailing 12-month revenue is $509.9 million with a 32.4% net profit margin. Year-over-year quarterly sales growth most recently was -0.3%. Analysts expect adjusted earnings to reach $0.797 per share for the current fiscal year. ADMA Biologics, Inc. does not currently pay a dividend.

How We Compare uniQure N.V., ADMA Biologics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at uniQure N.V., ADMA Biologics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

uniQure N.V., ADMA Biologics and Inc. Growth Grades

Company	Ticker	Growth
uniQure N.V.	QURE	F
ADMA Biologics, Inc.	ADMA	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

uniQure N.V. has a Growth Score of 4, which is Very Weak. ADMA Biologics, Inc. has a Growth Score of 37, which is Weak.

The Growth Stock Winner: No Clear Winner

Neither uniQure N.V., ADMA Biologics or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if uniQure N.V., ADMA Biologics or Inc. is the better investment when it comes to sustainable growth.

uniQure N.V., ADMA Biologics and Inc.’s Momentum Grades

Company	Ticker	Momentum
uniQure N.V.	QURE	A
ADMA Biologics, Inc.	ADMA	F

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

uniQure N.V. has a Momentum Score of 100, which is Very Strong. ADMA Biologics, Inc. has a Momentum Score of 13, which is Very Weak.

The Momentum Grade Winner: uniQure N.V.

As you can clearly see from the Momentum Grade breakdown above, uniQure N.V. is considered to have stronger momentum compared to ADMA Biologics, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, uniQure N.V. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

uniQure N.V., ADMA Biologics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
uniQure N.V.	QURE	F
ADMA Biologics, Inc.	ADMA	F

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

uniQure N.V. has a Earnings Estimate Score of 16, which is Very Negative. ADMA Biologics, Inc. has a Earnings Estimate Score of 15, which is Very Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither uniQure N.V., ADMA Biologics or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if uniQure N.V., ADMA Biologics or Inc. is the better investment when it comes to estimate revisions.

Other uniQure N.V., ADMA Biologics and Inc. Grades

In addition to Growth, Momentum and Estimate Revisions, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether uniQure N.V., ADMA Biologics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, uniQure N.V., ADMA Biologics or Inc. Stock?

Overall, uniQure N.V. stock has a Growth Score of 4, Momentum Score of 100 and Estimate Revisions Score of 16.

ADMA Biologics, Inc. stock has a Growth Score of 37, Momentum Score of 13 and Estimate Revisions Score of 15.

Comparing uniQure N.V., ADMA Biologics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.